ArticleCerebral circulation - cognition and behavior2026
Evaluating regional and global diffusion measures as biomarkers for vascular contributions to cognitive impairment and dementia.
Article in Cerebral circulation - cognition and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Regional diffusion imaging measures to disentangle SVD-related hypertensive arteriopathy versus cerebral amyloid angiopathy.Molecular neurodegeneration · 2026Article
- Imaging markers of vascular cognitive impairment: Current advances and future directions.Cerebral circulation - cognition and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Diffusion MRI (dMRI) has been proposed for quantifying early tissue changes in cerebral small vessel disease (SVD). We evaluated the regional dependance of predictors of white matter (WM) damage and compared the utility of longitudinal WM changes in the commonly available diffusion MRI measures for vascular contribution to cognitive impairment and dementia (VCID) prevention trials. Methods: We included 718 participants (mean age: 71.1(9.6) years, 56 % males) with at least two dMRI scans, amyloid-PET, and structural imaging. We computed single-shell dMRI measures (fractional anisotropy, mean diffusivity, free water, peak-width skeletonized mean diffusivity (PSMD) and assessed: i) regional dependance of predictors of baseline WM damage using voxel-level analyses; ii) longitudinal associations between dMRI measures and cognition; and iii) sample size estimates for a hypothetical clinical trial considering the regional and global dMRI measures as markers for VCID. We also included white matter hyperintensities (WMH) and our recently proposed composite vascular WM score (combination of WMH and fractional anisotropy of the genu) as a comparison. Results: Vascular risk was consistently associated with dMRI changes in the genu of the corpus callosum. All SVD markers correlated with cognitive performance longitudinally. Global free water and the composite score provided the smallest sample size estimates, especially in participants with prevalent vascular disease (aged 70-89). Conclusions: dMRI markers had significant frontal lobe changes due to vascular risk and were sensitive to cognitive decline. The composite vascular WM score, global free water, and WMH emerged as promising VCID biomarkers, but further validation is needed in multiple populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.